Myelodysplastic syndromes

Azacitidine.

Off

NICE appraisal

TA128 Azacitidine for the treatment of myelodyplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemia

DSU reports

Myelodysplastic syndromes – azacitidine: Review of Celgene’s response to the post-appeal ACD (PDF, 211KB) (December 2010)

Addendum to the September 2010 report by the Decision Support Unit (PDF, 12KB) (October 2010)

Myelodysplastic syndromes – Azacitidine: A critical appraisal of additional evidence submitted by Celgene and the MDS Foundation (PDF, 132KB) (September 2010)

Azacitidine STA Economic Model (PDF, 16KB) (September 2009)

DSU response to manufacturer’s revised model (PDF, 63KB) (December 2009)